Injection of vasoactive intestinal peptide into the eye improves corneal transplant survival

August 7, 2018, Elsevier
The effect of vasoactive intestinal peptide (VIP) treatment on high-risk corneal transplant survival. Animals underwent high-risk allogeneic corneal transplantation and received treatment with VIP at 1, 3, 5, 7, and 9 days after transplantation. A: VIP treatment significantly decreases graft opacity scores at 4 to 8 weeks post-transplantation (*P < 0.05, Mann-Whitney test). B: Weekly examination of grafts for 8 weeks demonstrates a significant increase in graft survival in VIP-treated mice compared with the controls (85% vs 0%; hazard ratio 0.10, 95% CI 0.04 to 0.26, ††††P < 0.0001, Log rank test). Each group consists of n=14. C: Representative confocal micrographs of central area of transplanted corneas in VIP-treated mice and in controls at 1, 2, and 8 weeks post-transplantation. Corneal endothelial cell-to-cell junction were stained and visualized with zonula occluden-1 (ZO-1, green). The scale bars are equal to 100μm (×400 magnification). D: Bar diagram of central corneal endothelial cell (CEnC) densities show significantly higher CEnC density in VIP-treated group compared with the control at 8 weeks post-transplantation (P = 0.02, Man-Whitney test). CEnC density in VIP-treated group did not reach statistical significance at weeks 1 and 2 after transplantation compared to the control (P = 0.11 and P = 0.06, respectively). Horizontal line represents the CEnC density of naïve age-matched C57BL/6 corneas. Each group consists of n=5 corneas. All data are presented as mean ±SEM, and data from one out of two independent experiments are shown. Credit: American Journal of Pathology

A new study in the American Journal of Pathology reports for the first time that injection of neuropeptide vasoactive intestinal peptide (VIP) directly into the eye of mice enhanced corneal graft survival. VIP produced other benefits, including acceleration of endothelial wound closure, protection of corneal endothelial cells (CEnCs), and improved corneal graft clarity. If proven successful in clinical studies, this novel approach may help alleviate visual loss in many patients with corneal disease.

"The successful outcome of mainly relies on the density and function of CEnCs, which keep the graft transparent. To improve the outcomes of corneal transplantation, various strategies have been employed to prevent immune-mediated graft rejection or enhance survival and function of CEnCs. However, an effective method has remained elusive so far," explained Ahmad Kheirkhah, MD, currently at University of Texas San Antonio, who completed the research when he was at the Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.

In this study, researchers evaluated the effect of VIP on corneal tissue in cell culture and living animals who received corneal transplants. VIP, a 28 amino acid neuropeptide, is recognized as an immunoregulatory and protective factor in various organ systems. VIP is found in the aqueous humor of the eye and may be secreted by CEnCs. Although it is known that VIP can help preserve the integrity of CEnCs and may be used by eye banks to improve the survival of donor corneas, until now it has been unclear whether administration of VIP in vivo after corneal transplantation could improve survival.

The researchers observed numerous ways in which VIP may exert beneficial effects. In cell cultures of human corneal endothelial cells, VIP accelerated wound healing compared to controls. When were exposed to the substances known to induce apoptosis (cell death), such as interferon-γ or tumor necrosis factor-α, VIP showed a dose-dependent protective effect.

In live mice who underwent corneal transplantation, grafts were more transparent in VIP-treated mice compared to controls four to eight weeks after transplantation. Eight weeks after transplantation, 85 percent of VIP-treated grafts survived compared to 0 percent of control grafts, and corneal endothelial cell density was higher in VIP-treated corneas compared to controls.

"Millions of patients around the world are blind due to corneal opacity, and they are in dire need of corneal transplantation. Unfortunately, there is a significant shortage of donor corneas across the world. On the other hand, many donated corneas cannot be used for transplantation due to inadequate endothelial . Moreover, corneal transplants can deteriorate over time due to continuous loss of CEnCs," noted Reza Dana, MD, MPH, MSc, Professor of Ophthalmology at the Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. "If confirmed in further clinical studies, we believe that the use of VIP will increase the number of donated corneas suitable for transplantation and improve the outcomes of corneal transplantation."

Corneal transplantation is the most common form of tissue transplantation in medicine today. These procedures are performed to correct the visual loss that occurs when the cornea, the transparent structure forming the front of the eye, becomes opaque (cloudy). Corneal opacity can result from many eye diseases.

Explore further: Corneal abnormalities seen with down syndrome

More information: "Vasoactive Intestinal Peptide Promotes Corneal Allograft Survival," American Journal of Pathology (2018). DOI: 10.1016/j.ajpath.2018.05.010

Related Stories

Corneal abnormalities seen with down syndrome

June 25, 2018
(HealthDay)—Patients with Down syndrome (DS) have steeper and thinner corneas and more corneal aberrations than patients without DS, according to a study published online June 21 in JAMA Ophthalmology.

New technique may prevent graft rejection in high-risk corneal transplant patients

May 1, 2017
Treating donor corneas with a cocktail of molecules prior to transplanting to a host may improve survival of grafts and, thus, outcomes in high-risk corneal transplant patients, according to a new study led by researchers ...

Stem cells may help improve corneal wound healing

July 31, 2017
A new review is the first to directly examine the role of various stem cells in the healing of wounded cornea, the outermost part of the eye. In contrast with most other reviews, it covers all major corneal cell types in ...

New study offers added hope for patients awaiting corneal transplants

January 9, 2018
New national research led by Jonathan Lass of Case Western Reserve University School of Medicine has found that corneal donor tissue can be safely stored for 11 days before transplantation surgery to correct eye problems ...

Study finds donor corneas can be safely preserved for longer period

November 10, 2017
Results from a large, national clinical trial show that corneal donor tissue can be safely stored for 11 days without negatively impacting the success of transplantation surgery to restore vision in people with diseases of ...

Development of new cornea endothelial cell lines provides powerful tool for understanding corneal cell biology

December 27, 2012
Human corneal endothelial cells (HCEnCs) form a monolayer of hexagonal cells whose main function is to maintain corneal clarity by regulating corneal hydration. Cell loss due to aging or corneal endothelial disorders, such ...

Recommended for you

Eating leafy greens could help prevent macular degeneration

October 19, 2018
A new study has shown that eating vegetable nitrates, found mainly in green leafy vegetables and beetroot, could help reduce your risk of developing early-stage age-related macular degeneration (AMD).

Widespread errors in 'proofreading' cause inherited blindness

October 12, 2018
Mistakes in "proofreading" the genetic code of retinal cells is the cause of a form of inherited blindness, retinitis pigmentosa (RP) caused by mutations in splicing factors.

Gene therapy breakthrough in treating rare form of blindness

October 9, 2018
Positive results of the world's first gene therapy trial for a genetic cause of blindness known as choroideremia have been reported in Nature Medicine.

Gene changes driving myopia reveal new focus for drug development

October 9, 2018
Myopia (nearsightedness) and hyperopia (farsightedness) develop through different molecular pathways, according to a new study publishing October 9 in the open-access journal PLOS Biology by Andrei Tkatchenko of Columbia ...

Dynamin-binding protein linked to congenital cataracts

October 4, 2018
Cataracts, a condition in which the eyes' natural lenses get clouded, are the most common cause of vision loss in older people and can be corrected by routine surgery. But congenital cataracts, which occur in infants and ...

Eye discovery to pave way for more successful corneal transplants

October 1, 2018
A team of eye specialists at The University of Nottingham has made another novel discovery that could help to improve the success of corneal transplants for patients whose sight has been affected by disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.